Clinical trials: open to volunteers, sponsored by Boryung Pharmaceutical Co., Ltd
Essential Hypertension, Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
- Trial name
- NCT06220773
- Testing
- BR1019A, BR1019B, BR1019C
- Where
- 3 sites in Indonesia, South Korea
- Volunteers
- 276 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421414
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421401
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT07421388
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-1 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421375
- Testing
- BR1015-A, BR1015-1, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Peripheral T Cell Lymphoma
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
- Trial name
- NCT07180771
- Testing
- BR101801
- Volunteers
- 44 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
- Trial name
- NCT07373613
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Metastatic Colorectal Cancer
A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.
This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line…
- Trial name
- NCT07263178
- Testing
- Second and later-line palliative chemotherapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Bipolar Disorder
A Study of Olanzapine in Participants With Bipolar Disorder.
This study aimed to identify treatment patterns in patients with bipolar disorder receiving olanzapine according to demographic and clinical characteristics and to evaluate the effectiveness of education on weight gain, a side…
- Trial name
- NCT07263191
- Testing
- Olanzapine
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
SCLC
Observational Study to Evaluate the Safety and Efficacy of Zepzelca™ Injection
The purpose of this study is to evaluate the safety and efficacy of Zepzelca™ inj. in real-world practice and to investigate important identified risks and gaps in information related to risk management plans.
- Trial name
- NCT06021483
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Hypertension
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
- Trial name
- NCT05970237
- Where
- South Korea
- Volunteers
- 9,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Schizophrenia
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Schedule in Patients With Schizophrenia
The objective of this clinical trial is to evaluate the safety and efficacy of olanzapine titration schedule in patients with schizophrenia
- Trial name
- NCT06821945
- Testing
- BR5402A, BR5402A-1, BR5402B
- Where
- 2 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Hypercholesterolemia, Mixed Dyslipidemia
A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition
- Trial name
- NCT06314919
- Where
- South Korea
- Volunteers
- 8,606 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension,Essential
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or…
- Trial name
- NCT05413057
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Breast Cancer
A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients
The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery
- Trial name
- NCT06537752
- Where
- 2 sites in South Korea
- Volunteers
- 1,052 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabete Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)
This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B,"…
- Trial name
- NCT07083401
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A"…
- Trial name
- NCT07083388
- Testing
- Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg, Dapagliflozin 10 mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd